Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of Nε-carboxymethyl lysine

Journal of Diabetes and its Complications

Volumn 24, Issue 6, 2010, Pages 424-432

  Kawai, Toshihide ^a   Takei, Izumi ^a   Tokui, Mikiya ^b   Funae, Osamu ^c   Miyamoto, Kazunori ^d   Tabata, Mitsuhisa ^a   Hirata, Takumi ^a   Saruta, Takao ^a   Shimada, Akira ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

^b Tokui Clinic   (Japan)

^c SAISEIKAI CENTRAL HOSPITAL   (Japan)

^d Yokohama Municipal Hospital   (Japan)

Author keywords

Diabetic peripheral neuropathy; Epalrestat; N Carboxymethyl lysine (CML); Nerve conduction study

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; EPALRESTAT; LIPID PEROXIDE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DRUG EFFECT; FEMALE; HUMAN; JAPANESE; LATENT PERIOD; LEG; MALE; MOTOR NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SENSORY NERVE CONDUCTION; SURAL NERVE; TIBIAL NERVE; VASCULAR DISEASE;

ALDEHYDE REDUCTASE; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MALE; MIDDLE AGED; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; RHODANINE; SURAL NERVE; THIAZOLIDINES; TIBIAL NERVE;

EID: 78049240469     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2008.10.005     Document Type: Article

References (52)

1. ε-carboxymethyllysine as a degeneration product of fructoselysine in glycated protein Journal of Biological Chemistry 261 1986 4889 4894
2. Andersen H., Stålberg E., and Falck B. F-Wave latency, the most sensitive nerve conduction parameter in patients with diabetes mellitus Muscle & Nerve 20 1997 1296 1302
3. Ando H., Takamura T., Nagai Y., Kaneko S. the Kanazawa University Multicenter Diabetes Study group Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy Journal of Diabetes and its Complications 20 2006 367 370
4. Baynes J.W., and Thorpe S.R. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm Diabetes 48 1999 1 9
5. Blankenberg S., Rupprecht H.J., Bickel C., Peetz D., Hafner G., and Tiret L. Circulating cell adhesion molecules and death in patients with coronary artery disease Circulation 104 2001 1336 1342
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
7. Brownlee M., Cerami A., and Vlassara H. Advanced glycosylation end products in tissue and the biomedical basis of diabetic complications New England Journal of Medicine 318 1988 1315 1321
8. Cameron N.E., Eaton S.E., Cotter M.A., and Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy Diabetologia 44 2001 1973 1988
9. Chang P.Y., Wu T.L., Tsao K.C., Li C.C., Sun C.F., and Wu J.T. Microplate ELISAs for soluble VCAM-1 and ICAM-1 Annals of Clinical & Laboratory Science 35 2005 312 317
10. Claus D., Mustafa C., Vogel W., Herz M., and Neundorfer B. Assessment of diabetic neuropathy: Definition of norm and discrimination of abnormal nerve function Muscle & Nerve 16 1993 757 768
11. Diabetes Control and Complications Trial (DCCT) research group Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial Annals of Neurology 38 1995 869 880
12. Fagius J., Brattberg A., Jameson S., and Berne C. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: A 24-week controlled trial Diabetologia 28 1985 323 329
13. Fisher M.A., Hoffen B., and Hultman C. Normative F-wave values and the number of recorded F waves Muscle & Nerve 17 1994 1185 1189
14. ε-(carboxymethyl) lysine, is a product of both peroxidation and glycooxidation reactions Journal of Biological Chemistry 271 1995 9982 9986
15. ε-Carboxymethyllysine in diabetic and non-diabetic polyneuropathies Acta Neuropathologica 104 2002 45 52
16. Hamada Y., Araki N., Horiuchi S., and Hotta N. Role of polyol pathway in nonenzymatic glycation Nephrology, Dialysis, Transplantation 11 1996 95 98
17. ε-(carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetic patients Diabetes Care 23 2000 1539 1544
18. Hotta N., Akanuma Y., Kawamori R., Matsuoka K., Oka Y., and Shichiri M. The ADCT study group: Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy Diabetes Care 29 2006 1538 1544
19. Hotta N., Sakamoto N., Shigeta Y., Kikkawa R., and Goto Y. Diabetic neuropathy study group in Japan: Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: Multicenter study Journal of Diabetes and its Complications 10 1996 168 172
20. ε-(carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes Diabetes, Obesity and Metabolism 7 2005 263 267
21. Ikeda T., Iwata K., and Tanaka Y. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus Diabetes Research and Clinical Practice 43 1999 193 198
22. Karachalias N., Babaei-Jadidi R., Ahmed N., and Thornalley P.J. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rat Biochemical Society Transactions 31 2003 1423 1425
23. Kasajima H., Yamagishi S., Sugai S., Yagihashi N., and Yagihashi S. Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients Virchows Archiv 439 2001 46 54
24. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections Diabetes Care 21 1998 1414 1431
25. Kohara N., Kimura J., Kaji R., Goto Y., Ishii J., and Takiguchi M. F-Wave latency serves as the most reproducible measure in nerve conduction studies of diabetic polyneuropathy: Multicentre analysis in healthy subjects and patients with diabetic polyneuropathy Diabetologia 43 2000 915 921
26. Krentz A.J., Honigsberger L., Ellis S.H., Hardman M., and Nattrass M. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy Diabetic Medicine 9 1992 463 468
27. Matsuoka K., Sakamoto N., Akanuma Y., Hotta N., Shichiri M., Toyota T. ADCT Study Group A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT) Diabetes Research and Clinical Practice 77S 2007 S263 S268
28. Mehrotra S., Ling K.L., Bekele Y., Gerbino E., and Earle K.A. Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with type 2 diabetes mellitus Diabetic Medicine 18 2001 109 115
29. Nakamura J., Kato K., Hamada Y., Nakayama M., Chaya S., and Nakashima E. A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats Diabetes 48 1999 2090 2095
30. Nakayama M., Nakamura J., Hamada Y., Chaya S., Mizubayashi R., and Yasuda Y. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy Diabetes Care 24 2001 1093 1098
31. Oates P.J. Polyol pathway and diabetic peripheral neuropathy International Review of Neurobiology 50 2002 325 392
32. Oates P.J., and Mylari B.L. Aldose reductase inhibitors: Therapeutic implications for diabetic complications Expert Opinion on Investigational Drugs 8 1999 2095 2119
33. Obrosova I.G. How does glucose generate oxidative stress in peripheral nerve? International Review of Neurobiology 50 2002 3 35
34. Ono Y., Aoki S., Ohnishi K., Yasuda T., Kawano K., and Tsukada Y. Increased serum levels of advanced glycation end-products and diabetic complications Diabetes Research and Clinical Practice 41 1998 131 137
35. Otsuki M., Hashimoto K., Morimoto Y., Kishimoto T., and Kasayama S. Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients Diabetes 46 1997 2096 2101
36. Partanen J., Niskanen L., Lehtinen J., Mervaala E., Siitonen O., and Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes mellitus New England Journal of Medicine 333 1995 89 94
37. Raskin P., and Rosenstock J. Aldose reductase inhibitors and diabetic complications American Journal of Medicine 83 1987 298 306
38. Schmidt A.M., Hori O., Chen J.X., Li J.F., Crandall J., and Zhang J. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes Journal of Clinical Investigation 96 1995 1395 1403
39. Stålberg E., and Falck B. Clinical motor nerve conduction studies Methods of Clinical Neurophysiology 4 1993 61 80
40. Steele J.W., Faulds D., and Goa K.L. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus Drugs & Aging 3 1993 532 555
41. ε-carboxymethyllysine- protein adducts, an advanced glycation endproduct Diabetologia 40 1997 1380 1387
42. Takahashi M., Lu Y.B., Myint T., Fujii J., Wada Y., and Taniguchi N. In vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: Identification of glycation sites Biochemistry 34 1995 1433 1438
43. Terashima H., Hama K., Yamamoto R., Tsuboshima M., Kikkawa R., and Hatanaka I. Effects of a new aldose reductase inhibitor on various tissues in vitro Journal of Pharmacology and Experimental Therapeutics 229 1984 226 230
44. Thornalley P.J. Glycation in diabetic neuropathy: Characteristics, consequences, causes, and therapeutic options International Review of Neurobiology 50 2002 37 57
45. Tsukushi S., Katsuzaki T., Aoyama I., Takayama F., Miyazaki T., and Shimokata K. Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: Role of the polyol pathway Kidney International 55 1999 1970 1976
46. Vinik A.I., and Mehrabyan A. Diabetic neuropathies The Medical Clinics of North America 88 2004 947 999
47. Vlassara H., and Palace M.R. Glycoxidation: The menace of diabetes and aging The Mount Sinai Journal of Medicine 70 2003 232 241
48. Wautier M.P., Boulanger E., Guillausseau P.J., Massin P., and Wautier J.L. AGEs, macrophage colony stimulating factor and vascular adhesion molecule blood levels are increased in patients with diabetic microangiopathy Thrombosis and Haemostasis 91 2004 879 885
49. Way K.J., Katai N., and King G.L. Protein kinase C and the development of diabetic vascular complications Diabetic Medicine 18 2001 945 959
50. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma Biochemical Medicine 15 1976 212 216
51. Yagihashi S., Yamagishi S., Wada R., Baba M., Hohman T.C., and Yabe-Nishimura C. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor Brain 124 2001 2448 2458
52. Yoon K.H., Lee J.H., Kim J.W., Cho J.H., Choi Y.H., and Ko S.H. Epidemic obesity and type 2 diabetes in Asia Lancet 368 2006 1681 1688